A Doubling Marker, a Small New Lesion, and a Trial That Never Finished
A single patient with a new, minimally symptomatic hepatic lesion five years after curative lung surgery. The disagreement is whether to treat a real growth signal now, or wait for symptoms to justify a therapy whose evidence base was built in a different disease.
L.B., 68, spent 34 years as the reference librarian at her town's public library before retiring, and still volunteers there weekly, “mostly so I have an excuse to read the new arrivals first.” Five years ago, an incidentally found lung nodule on a CT done for an unrelated fall led to a diagnosis of typical bronchial carcinoid, treated with curative-intent lobectomy; she has been followed with periodic surveillance since, without evidence of recurrence until three months ago, when a routine liver MRI found a new 1.4cm lesion with imaging characteristics suggestive of a neuroendocrine metastasis. Her chromogranin A — a blood marker that tracks neuroendocrine tumor burden — has roughly doubled over the same interval, a real biochemical signal of growth rather than an isolated abnormal number. She reports occasional facial flushing over the past several weeks, mild enough that she mentioned it to her husband before her doctor, and no diarrhea or wheezing to suggest a fuller carcinoid syndrome.
Somatostatin analog therapy has two genuinely separate jobs in a case like hers, and they don't require the same evidence to justify. As symptom control, it's essentially uncontroversial, effective against exactly the flushing she's starting to notice. As a drug meant to slow the tumor's actual growth, the evidence is thinner and, for lung-specific neuroendocrine tumors particularly, unsettled — the one randomized trial built specifically to test that question in patients like her closed early for lack of enrollment, before it could give a real answer either way. She has no other significant medical history beyond well-managed hypothyroidism, diagnosed years before her original carcinoid and unrelated to it, which the team mentions mostly to confirm there's no competing thyroid-driven explanation for her flushing before crediting it to the tumor.
A lesion that's growing, and a symptom that barely counts as one yet
Start a somatostatin analog now for antiproliferative intent. Two trials established that class effect: CLARINET, with lanreotide, in gastroenteropancreatic neuroendocrine tumors, and PROMID, with octreotide LAR, in midgut tumors. Acting on the growth signal now, while it's still a small lesion and a doubling marker rather than a symptomatic mass, is reasonable even without lung-NET-specific proof.
Note what you just did, though: you reached for two trials in two different drugs, and neither enrolled a lung primary. CLARINET was lanreotide in gastroenteropancreatic tumors; PROMID was octreotide in midgut tumors only. Her tumor is bronchial. SPINET — the one trial actually designed to answer this question in lung neuroendocrine tumors, and it used lanreotide — closed early for slow accrual without a clear positive result. Extrapolating across both the drug and the primary site assumes a biological similarity that hasn't been confirmed, and starting a monthly injectable with real gallstone and tolerability costs for a small, minimally symptomatic lesion trades a certain burden for an uncertain benefit.
You're right that doing nothing has its own cost if this really is early progression — but the one trial built to test this in her exact tumor type couldn't finish enrolling, and that's not a reason to treat borrowed evidence from a different organ as settled science.
Neither of you needs to win this argument today. Her flushing, however mild, is a real symptom-control indication on its own, entirely independent of the unresolved antiproliferative question — and both analogs carry that indication. Start therapy now on that basis. I'd use octreotide LAR, but I want the reason on the record: it is not that octreotide has the better antiproliferative case, because it doesn't — lanreotide is the analog with the labeled antitumor indication and the one both CLARINET and SPINET actually studied. It's that we are treating her flushing, where the two are interchangeable, and octreotide lets us confirm tolerance on a short-acting dose before committing her to a monthly depot. If the next scan pushes us toward treating growth rather than symptoms, that is the moment to switch to lanreotide, and we should say so now so nobody later mistakes today's choice for an antiproliferative one.
Agreed: start octreotide LAR, documented in her chart as symptom-indicated rather than an antiproliferative claim; imaging surveillance interval shortened to reassess growth trajectory independent of symptom response.
Not agreed: whether the shortened surveillance interval alone is an adequate substitute for a more directly antiproliferative approach if the next scan shows continued growth. The first oncologist sees it as a reasonable middle step; the second remains skeptical that watching a documented growth signal without treating it directly is truly equivalent caution.